文献速递心力衰竭与心肌病

抗miR-132减轻经皮主动脉缩窄动物模型中的心肌肥厚

AntimiR-132 Attenuates Myocardial Hypertrophy in an Animal Model of Percutaneous Aortic Constriction.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

本研究建立了一种经皮主动脉缩窄的猪压力超负荷心力衰竭模型,并在d0和d28经冠状动脉内注射抑制miR-132的反义寡核苷酸。d56时,抗miR-132治疗减小了心肌细胞横截面积、改善了整体心功能、减轻了间质纤维化增加并提高了毛细血管密度,提示抑制miR-132是预防肥厚性心脏病心力衰竭进展的有效策略。

要点

  • 抗miR-132减小压力超负荷猪模型的心肌细胞横截面积。
  • 抗miR-132改善整体心功能并减轻间质纤维化增加。
  • 抗miR-132提高心脏毛细血管密度,可能延缓心衰进展。

核心结论

  • 抑制miR-132是预防肥厚性心脏病中心力衰竭进展的有效策略,可能开发为非缺血性心力衰竭的治疗方法。

研究设计与样本

  • 研究建立了经皮主动脉缩窄的猪压力超负荷心力衰竭模型,通过胸主动脉植入经皮缩窄支架诱导进行性重构。
  • 在d0(经皮横向主动脉缩窄诱导)和d28经冠状动脉内局部给予抑制miR-132的反义寡核苷酸(antimiR-132)。

主要发现

  • d56时,抗miR-132治疗组心肌细胞横截面积小于未治疗肥厚心脏组(188.9 ± 2.8 vs. 258.4 ± 9.0 μm2)。
  • d56时,抗miR-132治疗组整体心脏功能改善,射血分数高于对照组(48.9 ± 1.0% vs. 36.1 ± 1.7%)。
  • d56时,抗miR-132治疗组间质纤维化增加程度低于对照组(Δsham 1.8 ± 0.5% vs. Δsham 10.8 ± 0.6%)。
  • d56时,抗miR-132治疗组心脏血小板内皮细胞黏附分子1+毛细血管密度高于对照组(647 ± 20 cells/mm2 vs. 485 ± 23 cells/mm2)。

临床怎么用

  • 在压力超负荷相关心肌肥厚和心力衰竭进程中,抑制miR-132可能作为延缓心衰进展的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pathological cardiac hypertrophy is a result of afterload-increasing pathologies including untreated hypertension and aortic stenosis. It features progressive adverse cardiac remodeling, myocardial dysfunction, capillary rarefaction, and interstitial fibrosis often leading to heart failure. OBJECTIVES: This study aimed to establish a novel porcine model of pressure-overload-induced heart failure and to determine the effect of inhibition of microribonucleic acid 132 (miR-132) on heart failure development in this model. METHODS: This study developed a novel porcine model of percutaneous aortic constriction by implantation of a percutaneous reduction stent in the thoracic aorta, inducing progressive remodeling at day 56 (d56) after pressure-overload induction. In this study, an antisense oligonucleotide specifically inhibiting miR-132 (antimiR-132), was regionally applied via intracoronary injection at d0 (percutaneous transverse aortic constriction induction) and d28. RESULTS: At d56, antimiR-132 treatment diminished cardiomyocyte cross-sectional area (188.9 ± 2.8 vs. 258.4 ± 9.0 μm2 in untreated hypertrophic hearts) and improved global cardiac function (ejection fraction 48.9 ± 1.0% vs. 36.1 ± 1.7% in control hearts). Moreover, at d56 antimiR-132-treated hearts displayed less increase of interstitial fibrosis compared with sham-operated hearts (Δsham 1.8 ± 0.5%) than control hearts (Δsham 10.8 ± 0.6%). Of note, cardiac platelet and endothelial cell adhesion molecule 1+ capillary density was higher in the antimiR-132-treated hearts (647 ± 20 cells/mm2) compared with in the control group (485 ± 23 cells/mm2). CONCLUSIONS: The inhibition of miR-132 is a valid strategy in prevention of heart failure progression in hypertrophic heart disease and may be developed as a treatment for heart failure of nonischemic origin.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Hinkel R, Batkai S, Bähr A, et al. AntimiR-132 Attenuates Myocardial Hypertrophy in an Animal Model of Percutaneous Aortic Constriction. J Am Coll Cardiol. 2021. PMID: 34112319. doi:10.1016/j.jacc.2021.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。